ACAD
31.07
-0.15
-0.48%
AEMD
0.25
-0.01
-4.48%
APRI
1.42
+0.09
+6.99%
ARNA
4.5
-0.06
-1.32%
ATEC
1.3
0.00
0.00%
CFN
59.59
+0.03
+0.04%
CNAT
5.98
+0.19
+3.28%
CRXM
0.21
0.00
0.00%
CYTX
0.48
0.00
0.00%
DXCM
61
+0.41
+0.68%
GNMK
13.3
+0.19
+1.45%
HALO
14.59
+0.44
+3.07%
ILMN
200.01
+2.15
+1.09%
INNV
0.21
+0.01
+4.95%
INO
8.5
0.00
0.00%
ISCO
0.06
+0.00
+7.83%
ISIS
69.88
+1.3
+1.90%
LGND
56.88
-0.54
-0.94%
LPTN
2.79
-0.1
-3.46%
MBVX
1.05
-0.1
-8.70%
MEIP
3.84
+0.12
+3.23%
MNOV
3.8
+0.01
+0.26%
MRTX
21.34
+0.88
+4.30%
MSTX
0.43
-0.02
-3.98%
NBIX
34.29
+0.9
+2.70%
NUVA
47.28
+0.81
+1.74%
ONCS
0.37
-0.02
-5.19%
ONVO
6.68
+0.19
+2.93%
OREX
5.34
-0.16
-2.82%
OTIC
31.75
+0.02
+0.06%
QDEL
24.45
+0.09
+0.37%
RCPT
112.71
-0.36
-0.32%
RGLS
18.63
+0.97
+5.49%
RMD
63.09
-0.23
-0.36%
SCIE
0.01
0.00
-9.60%
SPHS
0.47
+0.03
+6.59%
SRNE
10.73
+0.34
+3.27%
TROV
5.83
-0.02
-0.34%
VICL
1.05
+0.02
+1.46%
VOLC
17.98
+0.02
+0.11%
ZGNX
1.37
-0.02
-1.09%
Home » Archive by Category

Xconomy

New Research Could (Finally) Remove RNAi’s Commercial Limitations

November 17, 2014 – 9:05 am | Edit Post

[Corrected 11/17/14, 12:30pm. See below.] If nothing else, the acronym RNAi, which stands for ribonucleic acid interference, should be familiar to biotech observers as something that won two…

[[Click headline to continue reading.]]

Device Maker Says Ebola Patient Recovered After Blood Filtration

November 14, 2014 – 9:10 am | Edit Post

As the global death toll from the current Ebola outbreak officially hit 5,147 this week, a San Diego medical device company is reporting promising findings in the treatment of one infected patient….

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Intarcia, Dendreon, Amgen, Doudna & More

November 13, 2014 – 12:16 pm | Edit Post

[Corrected 11/13/14, 5:40 pm. See below.] West Coast spotlights this week are on new ways to fight disease. Some are close to getting to market: Amgen announced late-stage development and regulatory…

[[Click headline to continue reading.]]

With Wires and Electrodes, Tara Bio Builds a Heart on a Chip

November 12, 2014 – 4:28 am | Edit Post

It’s been pretty clear for some time that there’s a big need to improve the efficiency of drug R&D. By industry’s count, drugs cost over $1 billion to develop, and most of them fail. A big…
[[Click headline to continue reading.]]

Lowering the Cost of Failure in Biopharmaceuticals

November 11, 2014 – 1:00 am | Edit Post

In any business, projects fail, but in biopharmaceuticals, the consequences of failure are especially damaging. Projects in the industry tend to be long and expensive—from clinical trials to…
[[Click headline to continue reading.]]

DMI Diagnostic Device Wins Grand Prize in Nokia Sensing XPrize

November 10, 2014 – 7:00 am | Edit Post

The XPrize Foundation returned to San Diego today to announce that a team led by Eugene Y. Chan of the DNA Medicine Institute (DMI) in Cambridge, MA, is the winner of the second $525,000 grand prize…

[[Click headline to continue reading.]]

Beg, Borrow, or Steal: Accessing Unaffordable Science Journals

November 10, 2014 – 1:00 am | Edit Post

If you work in academia or in Big Pharma, you likely have easy access to the world’s scientific literature. Outside of these places, however, obtaining affordable access to the latest scientific…
[[Click headline to continue reading.]]

Beg, Borrow, or Steal: Accessing Unaffordable Science Journals

November 10, 2014 – 1:00 am | Edit Post

If you work in academia or in Big Pharma, you likely have easy access to the world’s scientific literature. Outside of these places, however, obtaining affordable access to the latest scientific…
[[Click headline to continue reading.]]

West Coast Biotech Roundup: Nevro, Coherus, Xenon, Rock Health, Etc.

November 6, 2014 – 11:56 am | Edit Post

The first week of November has brought the first taste of winter to much of the U.S., plenty of sunshine to California, and a flurry of IPOs. There have been three so far on the West Coast, the main…

[[Click headline to continue reading.]]

AbbVie Plunks Down $275M Upfront for Infinity’s Blood Cancer Drug

September 3, 2014 – 4:56 am | Edit Post
AbbVie Plunks Down $275M Upfront for Infinity’s Blood Cancer Drug

It’s been a topsy-turvy few years for Infinity Pharmaceuticals. The Cambridge, MA-based company is well behind a few others, whose rival blood cancer drugs that have already made it to market, and…

[[Click headline to continue reading.]]